查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1751198

生长抑制素类似物市场规模、份额、趋势分析报告：按类型、应用、最终用途、地区、细分市场预测，2025-2030

Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, NET), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

生长抑制素类似物市场的成长与趋势：

根据 Grand View Research 的新报告，全球生长抑制素类似物市场规模预计到 2030 年将达到 111 亿美元，2025 年至 2030 年的复合年增长率为 13.3%。

提高对肢端肥大症和神经内分泌肿瘤等疾病的认识有望成为产生影响的关键驱动因素。

肢端肥大症是一种慢性内分泌疾病，由生长激素分泌过多引起，通常由脑下垂体腺瘤引起。据估计，到2023年，全球每百万人中约有4600人患有肢端肥大症，每年每百万人中诊断出116.9例新病例，且这一数字还在持续上升。此病通常在男性40岁左右、女性45岁左右确诊，但通常在三岁时开始发病。因此，肢端肥大症盛行率的上升正在推动生长抑制素类似物市场的发展。

韩国、日本和印度等国家神经内分泌癌（NET）诊断率的上升和人均收入的提高是市场的主要驱动力。此外，製药公司不断增加的投资预计也将创造丰厚的成长机会。各种提供各种疾病相关资讯的线上入口网站的出现，预计将提高人们的认知度。例如，神经内分泌癌认知网络 (NIOEN) 提供与症状、可用治疗方案和疾病管理相关的所有资讯。

生长抑制素类似物市场亮点

  • 根据类型，Octreotide在生长抑制素类似物市场占据主导地位，2024 年的销售份额为 36.3%。
  • 预计在预测期内，Pasireotide部分将以最快的复合年增长率成长。
  • 根据应用，NETs 部门预计将在 2024 年占据最大的收益占有率，主导生长抑制素类似物市场，并在预测期内以最快的复合年增长率成长。
  • 医院是生长抑制素类似物市场的主导者，在 2024 年占据最大的收益占有率。
  • 2024 年，医院将占据市场主导地位，而诊所领域预计将以最快的速度成长，预测期内复合年增长率为 14.4%。
  • 由于该地区主要参与者的存在，北美占据了全球市场的主导地位。

目录

第一章调查方法与范围

第二章执行摘要

第三章生长抑制素类似物市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章生长抑制素类似物市场：按类型分類的商业分析

  • 2024 年及 2030 年各类型市场占有率
  • 类型细分细分仪表板
  • 按类型分類的市场规模、预测和趋势分析（2018-2030 年）
  • Octreotide
  • Lanreotide
  • Pasireotide
  • 其他的

第五章生长抑制素类似物市场：按应用进行的业务分析

  • 2024 年及 2030 年各应用领域的市场占有率
  • 应用程式细分仪表板
  • 市场规模、预测与趋势分析（按应用，2018-2030 年）
  • 肢端肥大症
  • NET
  • 其他的

第六章生长抑制素类似物市场：依最终用途进行的商业分析

  • 2024 年和 2030 年按最终用途分類的市场占有率
  • 最终用途细分仪表板
  • 按最终用途分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院
  • 诊所
  • 其他的

第七章生长抑制素类似物市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 市场规模、预测趋势分析，2018 年至 2030 年：
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年各国情况
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
    • 俄罗斯
  • 亚太地区
    • 2018-2030年各国情况
    • 印度
    • 中国
    • 韩国
    • 香港
    • 澳洲
    • 新加坡
    • 日本
    • 泰国
  • 拉丁美洲
    • 2018-2030年各国情况
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年各国情况
    • 科威特
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国

第八章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/列表
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Eli Lilly and Company
    • Medical Device Business Services, Inc.
    • Johnson &Johnson Services, Inc.
    • Stryker
    • Ultragenyx Pharmaceutical Inc.
    • Alexion Pharmaceuticals, Inc.
Product Code: GVR-3-68038-789-6

Somatostatin Analogs Market Growth & Trends:

The global somatostatin analogs market size is anticipated to reach USD 11.1 billion by 2030 and expand at a CAGR of 13.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.

The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

Somatostatin Analogs Market Highlights

  • By type, octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024.
  • The pasireotide segment is expected to grow at the fastest CAGR over the forecast period.
  • By application, the NET segment dominated the somatostatin analogs market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
  • Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024.
  • Hospitals dominated the market in 2024, and the clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period.
  • North America dominated the global market owing to the presence of key players in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Somatostatin Analogs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Somatostatin Analogs Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Octreotide
    • 4.4.1. Octreotide Market, 2018 - 2030 (USD Million)
  • 4.5. Lanreotide
    • 4.5.1. Lanreotide Market, 2018 - 2030 (USD Million)
  • 4.6. Pasireotide
    • 4.6.1. Pasireotide Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 5. Somatostatin Analogs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Acromegaly
    • 5.4.1. Somatostatin Analogs Market, in Acromegaly, 2018 - 2030 (USD Million)
  • 5.5. NET
    • 5.5.1. Somatostatin Analogs Market, in NET, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Somatostatin Analogs Market, in Others, 2018 - 2030 (USD Million)

Chapter 6. Somatostatin Analogs Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Segment Market, 2018 - 2030 (USD Million)
  • 6.5. Clinics
    • 6.5.1. Clinics Segment Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 7. Somatostatin Analogs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.10. Russia
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Regulatory Framework
      • 7.5.10.3. Competitive Insights
      • 7.5.10.4. Russia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. India Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. South Korea Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Hong Kong
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Hong Kong Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Singapore
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Singapore Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.8. Japan
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Regulatory Framework
      • 7.6.8.3. Competitive Insights
      • 7.6.8.4. Japan Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.9. Thailand
      • 7.6.9.1. Key Country Dynamics
      • 7.6.9.2. Regulatory Framework
      • 7.6.9.3. Competitive Insights
      • 7.6.9.4. Thailand Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. Kuwait
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. Kuwait Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. South Africa
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. South Africa Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. UAE
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. UAE Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Novo Nordisk A/S
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eli Lilly and Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Medical Device Business Services, Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Johnson & Johnson Services, Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Stryker
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Ultragenyx Pharmaceutical Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Alexion Pharmaceuticals, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global somatostatin analogs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 5. Global somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 6. Global somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 7. North America somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 9. North America somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 10. North America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 11. U.S. somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 12. U.S. somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 13. U.S. somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 14. Canada somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 15. Canada somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 16. Canada somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 17. Mexico somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 18. Mexico somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 19. Mexico somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 20. Europe somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 22. Europe somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 23. Europe somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 24. UK somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 25. UK somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 26. UK somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 27. Germany somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 28. Germany somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 29. Germany somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 30. France somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 31. France somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 32. France somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 33. Italy somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 34. Italy somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 35. Italy somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 36. Spain somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 37. Spain somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 38. Spain somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 39. Denmark somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 40. Denmark somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 41. Denmark somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 42. Sweden somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 43. Sweden somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 44. Sweden somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 45. Norway somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 46. Norway somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 47. Norway somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 48. Russia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 49. Russia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 50. Russia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 52. Asia Pacific somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 53. Asia Pacific somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 54. Asia Pacific somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 55. India somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 56. India somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 57. India somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 58. China somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 59. China somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 60. China somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 61. South Korea somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 62. South Korea somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 63. South Korea somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 64. Hong Kong somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 65. Hong Kong somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 66. Hong Kong somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 67. Australia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 68. Australia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 69. Australia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 70. Singapore somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 71. Singapore somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 72. Singapore somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 73. Japan somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 74. Japan somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 75. Japan somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 76. Thailand somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 77. Thailand somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 78. Thailand somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 79. Latin America somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 80. Latin America somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 81. Latin America somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 82. Latin America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 83. Brazil somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 84. Brazil somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 85. Brazil somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 86. Argentina somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 87. Argentina somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 88. Argentina somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 89. Middle East & Africa somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 90. Middle East & Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 91. Middle East & Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 92. Middle East & Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 93. Kuwait somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 94. Kuwait somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 95. Kuwait somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 96. Saudi Arabia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 97. Saudi Arabia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 98. Saudi Arabia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 99. South Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 100. South Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 101. South Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 102. UAE somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 103. UAE somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 104. UAE somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Somatostatin analogs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type outlook (USD Million)
  • Fig. 10 Application outlook (USD Million)
  • Fig. 11 End Use outlook (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Somatostatin analogs market dynamics
  • Fig. 14 Somatostatin analogs market: Porter's five forces analysis
  • Fig. 15 Somatostatin analogs market: Pestle analysis
  • Fig. 16 Somatostatin analogs market: Type segment dashboard
  • Fig. 17 Somatostatin analogs market: Type market share analysis, 2024 & 2030
  • Fig. 18 Octreotide market, 2018 - 2030 (USD Million)
  • Fig. 19 Lanreotide market, 2018 - 2030 (USD Million)
  • Fig. 20 Pasireotide market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 Somatostatin analogs market: Application segment dashboard
  • Fig. 23 Somatostatin analogs market: Application market share analysis, 2024 & 2030
  • Fig. 24 Somatostatin analogs market, in Acromegaly, 2018 - 2030 (USD Million)
  • Fig. 25 Somatostatin analogs market, in NET, 2018 - 2030 (USD Million)
  • Fig. 26 Somatostatin analogs market, in Others, 2018 - 2030 (USD Million)
  • Fig. 27 Somatostatin analogs market: End Use segment dashboard
  • Fig. 28 Somatostatin analogs market: End Use market share analysis, 2024 & 2030
  • Fig. 29 Hospitals segment market, 2018 - 2030 (USD Million)
  • Fig. 30 Clinics segment market, 2018 - 2030 (USD Million)
  • Fig. 31 Others segment market, 2018 - 2030 (USD Million)
  • Fig. 32 Somatostatin analogs market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 57 Norway country dynamics
  • Fig. 58 Norway somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 59 Russia country dynamics
  • Fig. 60 Russia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 64 China country dynamics
  • Fig. 65 China somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 68 Hong Kong country dynamics
  • Fig. 69 Hong Kong somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 70 Australia country dynamics
  • Fig. 71 Australia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 72 Singapore country dynamics
  • Fig. 73 Singapore somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 74 Japan country dynamics
  • Fig. 75 Japan somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 76 Thailand country dynamics
  • Fig. 77 Thailand somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil country dynamics
  • Fig. 80 Brazil somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina country dynamics
  • Fig. 82 Argentina somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East & Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa country dynamics
  • Fig. 85 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait country dynamics
  • Fig. 87 Kuwait somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia country dynamics
  • Fig. 89 Saudi Arabia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 90 South Africa country dynamics
  • Fig. 91 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 92 UAE country dynamics
  • Fig. 93 UAE somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework